Med (New York, N.Y.)HumansHypertriglyceridemiaApolipoprotein C-IIIOligonucleotidesAntisense
Olezarsen in moderate hypertriglyceridemia: The Essence-TIMI 73b trial.
Ioanna Gouni-Berthold
Published: 202510.1016/j.medj.2025.100923
Abstract
The Essence-TIMI 73b trial demonstrated that monthly injections of olezarsen, an antisense oligonucleotide targeting hepatic APOC3, over 6 months increased HDL cholesterol and significantly decreased the concentrations of triglycerides, apolipoprotei…
Preview only. Read the full abstract at the source